Select Page

BL-1040, a medical device developed for the prevention of cardiac remodeling in acute myocardial infarction patients, which was out-licensed to Bellerophon Therapeutics (f/k/a Ikaria) (in pivotal CE Mark registration trial); BL-8040, for acute myeloid leukemia (AML) and other hematological cancers (in midst of Phase II trial for AML and Phase I trial for stem-cell mobilization); BL-7010, a novel, non-absorbable, high molecular weight polymer intended for the treatment of celiac disease (Phase I/II trial successfully completed); BL-5010, a novel formulation for the non-surgical removal of skin lesions (Phase I/II trial successfully completed), which was out-licensed to Omega Pharma in the territories of Europe, Australia and additional selected countries; BL-7040, a novel, orally available synthetic oligonucleotide for the treatment of inflammatory bowel disease (Phase IIa trial successfully completed); BL-8020, an orally available interferon-free treatment for Hepatitis C (HCV) and other viral indications (in Phase I/II development), which has been partnered with Genoscience and Panmed. Additional compounds are currently in the pipeline at various stages of pre-clinical development.]]>